Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 03, 2026 | June 05, 2026 |
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| LENZ Therapeutics, Inc.LENZ · Entity 6475 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,300 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,500 · Balance 48,300 F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2036-06-03 | Direct | 53,250 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 53,250 · Balance 53,250 F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
LENZ Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.63 · Expires 2036-06-15 | Direct | 22,100 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 22,100 · Balance 22,100 F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 04, 2023
Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-05-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-03 · Other · Disposed 25,751 · Balance 40,267 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effectve as of May 3, 2023 (the "Effective Time"). F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto. Row 2 · 2023-05-03 · Other · Disposed 40,267 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.36 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-03 · Disposition to issuer · Disposed 206,005 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.02 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-03 · Disposition to issuer · Disposed 8,130 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.56 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-03 · Disposition to issuer · Disposed 77,235 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.98 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-03 · Disposition to issuer · Disposed 97,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-03 · Disposition to issuer · Disposed 44,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-05-03 · Disposition to issuer · Disposed 53,400 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-05-03 · Disposition to issuer · Disposed 44,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-05-03 · Disposition to issuer · Disposed 55,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effectve as of May 3, 2023 (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
KINETA, INC./DE
Report date June 30, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Disposition to issuer · Disposed 13,794 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.58 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").
F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.
F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.
F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 00:18 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 22,100 | $0.00 Strike: $6.63 | $0.00 |
DisclosureSEC source: 0001340881-26-000001 · wk-form4_1781569095.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,100 Underlying: Common Stock · 22,100 shares Expires 2036-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:39 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262290 · ownership.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 53,250 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001628280-26-041276 · wk-form4_1780691492.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 Underlying: Common Stock · 53,250 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:31 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041276 · wk-form4_1780691492.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,300 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:33 UTC | KINETA, INC./DE KANT · Entity 77778 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-25-093062 · ownership.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:33 UTC | KINETA, INC./DE KANT · Entity 77778 | Disposition to issuerCommon Stock | 13,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-093062 · ownership.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3 · price: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. Read SEC document |
| June 25, 2025 Filed Jun 25, 2025 21:55 UTC | KINETA, INC./DE KANT · Entity 77778 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090145 · ownership.xml · nonDerivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,794 Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:55 UTC | KINETA, INC./DE KANT · Entity 77778 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-25-090145 · ownership.xml · derivative · entry 4 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:55 UTC | KINETA, INC./DE KANT · Entity 77778 | Tax withholdingCommon Stock | 4,706 | $0.26 | $1,223.56 |
DisclosureSEC source: 0000950170-25-090145 · ownership.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,794 Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:55 UTC | KINETA, INC./DE KANT · Entity 77778 | Exercise / conversionCommon Stock | 12,500 | $0.61 | $7,637.50 |
DisclosureSEC source: 0000950170-25-090145 · ownership.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000047 · wk-form4_1749678389.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001576885-25-000081 · wk-form4_1749156855.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-06-04 F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:57 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000081 · wk-form4_1749156855.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:14 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082335 · ownership.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:21 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000950170-25-048555 · ownership.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-27 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from March 28, 2025 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 16:19 UTC | KINETA, INC./DE KA · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-24-104013 · ownership.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 F1 · derivative.exercise_date: The stock option will vest in equal quarterly installments over one year following June 21, 2024, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 20:40 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001576885-24-000075 · wk-form4_1718052003.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:39 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000026 · wk-form4_1711413562.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| July 28, 2023 Filed Aug 2, 2023 00:09 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-044075 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 28, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 16:18 UTC | KINETA, INC./DE KA · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-23-041031 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The stock option will vest in equal quarterly installments over three years following July 1, 2023, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:40 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001576885-23-000032 · wk-form4_1686174010.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $7.56 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 10 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,500 | Not disclosed Strike: $11.89 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 9 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 53,400 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 8 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,400 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,500 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 7 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 97,500 | Not disclosed Strike: $23.98 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 6 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 77,235 | Not disclosed Strike: $9.56 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 5 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,235 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,130 | Not disclosed Strike: $4.02 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 4 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,130 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 206,005 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · derivative · entry 3 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 206,005 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 40,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 25,751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001640455-23-000107 · wf-form4_168320059150670.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · President, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,267 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effectve as of May 3, 2023 (the "Effective Time"). F2 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto. F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding and unvested restricted stock unit settleable in Shares (each, a "Company RSU") vested in full, was cancelled and converted into the right to receive (i) the product of (A) the total number of Shares then underlying such Company RSU multiplied by (B) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 20:30 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 7,781 | $1.12 | $8,714.72 |
DisclosureSEC source: 0001640455-23-000009 · wf-form4_167348700319650.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,018 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: Represents the weighted average share price of an aggregate total of 7,781 shares sold in the price range of $1.05 to $1.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 20:30 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 6,315 | $1.10 | $6,946.50 |
DisclosureSEC source: 0001640455-23-000009 · wf-form4_167348700319650.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,799 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 6,315 shares sold in the price range of $1.03 to $1.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:22 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-037864 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:11 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option Grant (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001209191-22-022535 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:38 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001640455-22-000018 · wf-form4_164393506966078.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The option will vest quarterly in 16 equal installments following January 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 19:38 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001640455-22-000018 · wf-form4_164393506966078.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,114 Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 20:56 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 8,222 | $6.65 | $54,676.30 |
DisclosureSEC source: 0001640455-22-000009 · wf-form4_164195255982357.xml · nonDerivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,614 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: Represents the weighted average share price of an aggregate total of 8,222 shares sold in the price range of $6.57 to $6.90 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 20:56 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 4,595 | $7.30 | $33,543.50 |
DisclosureSEC source: 0001640455-22-000009 · wf-form4_164195255982357.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,836 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Represents the weighted average share price of an aggregate total of 4,595 shares sold in the price range of $7.03 to $7.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 14,800 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0000899243-21-022018 · doc4.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock · 14,800 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:46 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 44,500 | $0.00 Strike: $11.89 | $0.00 |
DisclosureSEC source: 0001640455-21-000028 · wf-form4_161239239254752.xml · derivative · entry 2 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2031-02-01 F1 · derivative.exercise_date: The option will vest quarterly in 16 equal installments following January 1, 2021. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 17:46 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantCommon Stock | 22,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001640455-21-000028 · wf-form4_161239239254752.xml · nonDerivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,431 Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,799 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · derivative · entry 11 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,005 Underlying: Common Stock · 3,799 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F7 · derivative.exercise_date: 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 3,799 | $12.00 | $45,588.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 7 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,181 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F4 · price: Represents the weighted average share price of an aggregate total of 3,799 shares sold at $12.00 and $12.01 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionCommon Stock | 3,799 | $2.36 | $8,965.64 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 6 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,710 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · derivative · entry 10 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,804 Underlying: Common Stock · 3,710 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F7 · derivative.exercise_date: 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,775 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · derivative · entry 9 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,775 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F6 · derivative.exercise_date: The option shares vested and became exercisable in 12 monthly installments from October 9, 2014. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,016 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · derivative · entry 8 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,016 shares Expires 2024-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F5 · derivative.exercise_date: The option shares vested and became exercisable in 12 monthly installments from October 9, 2013. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 10,000 | $10.03 | $100,300.00 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 5 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,181 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F3 · price: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $10.00 to $10.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 18:35 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | SaleCommon Stock | 16,201 | $12.03 | $194,898.03 |
DisclosureSEC source: 0001640455-21-000016 · wf-form4_161135854303039.xml · nonDerivative · entry 4 Drapkin Kimberlee C · CIK 0001340881 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,181 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. F2 · price: Represents the weighted average share price of an aggregate total of 16,201 shares sold in the price range of $12.00 to $12.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.